HQSI (Healthcare Quality Strategies, Inc)

hqsi.org

HQSI (Healthcare Quality Strategies, Inc.) provides independent medical review for private and government insurers, hospitals, third-party administrators and employers. As a URAC-certified review organization, and NAIRO member, HQSI conducts reviews in all key medical specialties always adhering to the highest ethical and professional standards.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

BIODESIX ANNOUNCES SENIOR SECURED FINANCING AGREEMENT WITH PERCEPTIVE ADVISORS FOR UP TO $50 MILLION

Biodesix | November 17, 2022

news image

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. This debt capital, which is conditioned on the Company raising at least $30 millio...

Read More

OPKO HEALTH ACQUIRES MODEX THERAPEUTICS, GAINS PROPRIETARY IMMUNOTHERAPY TECHNOLOGY WITH A FOCUS ON ONCOLOGY AND INFECTIOUS DISEASES

OPKO Health | May 10, 2022

news image

OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. OPKO acquired ModeX for $300 million in OPKO common stock. Founded in October 2020 with headquarters in Natick, Mass., ModeX Therapeutics has developed highly flexible multi-specific antibody t...

Read More

MEDICAL

AMBAGON THERAPEUTICS LAUNCHES WITH $85 MILLION SERIES A TO ADVANCE PIONEERING MOLECULAR GLUE PLATFORM AND PROGRESS PIPELINE

Ambagon Therapeutics | January 07, 2022

news image

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined th...

Read More

MEDTECH

NOVOZYMES AND SAIPEM ENTER COLLABORATION AGREEMENT TO CREATE A MORE SUSTAINABLE CO2 CAPTURE

Novozymes | December 13, 2021

news image

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzym...

Read More
news image

CELL AND GENE THERAPY

BIODESIX ANNOUNCES SENIOR SECURED FINANCING AGREEMENT WITH PERCEPTIVE ADVISORS FOR UP TO $50 MILLION

Biodesix | November 17, 2022

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. This debt capital, which is conditioned on the Company raising at least $30 millio...

Read More
news image

OPKO HEALTH ACQUIRES MODEX THERAPEUTICS, GAINS PROPRIETARY IMMUNOTHERAPY TECHNOLOGY WITH A FOCUS ON ONCOLOGY AND INFECTIOUS DISEASES

OPKO Health | May 10, 2022

OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. OPKO acquired ModeX for $300 million in OPKO common stock. Founded in October 2020 with headquarters in Natick, Mass., ModeX Therapeutics has developed highly flexible multi-specific antibody t...

Read More
news image

MEDICAL

AMBAGON THERAPEUTICS LAUNCHES WITH $85 MILLION SERIES A TO ADVANCE PIONEERING MOLECULAR GLUE PLATFORM AND PROGRESS PIPELINE

Ambagon Therapeutics | January 07, 2022

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined th...

Read More
news image

MEDTECH

NOVOZYMES AND SAIPEM ENTER COLLABORATION AGREEMENT TO CREATE A MORE SUSTAINABLE CO2 CAPTURE

Novozymes | December 13, 2021

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzym...

Read More